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Abstract
Background: The main reason for anemia in renal failure patients is the insufficient erythropoietin production by
the kidneys. Beside erythropoietin deficiency, in vitro studies have incriminated uremic toxins in the
pathophysiology of anemia but clinical data are sparse. In order to assess if indole 3-acetic acid (IAA), indoxyl sulfate
(IS), and paracresyl sulfate (PCS) -three protein bound uremic toxins- are clinically implicated in end-stage renal
disease anemia we studied the correlation between IAA, IS and PCS plasmatic concentrations with hemoglobin and
Erythropoietin Stimulating Agents (ESA) use in hemodialysis patients.
Methods: Between June and July 2014, we conducted an observational cross sectional study in two hemodialysis
center. Three statistical approaches were conducted. First, we compared patients treated with ESA and those not
treated. Second, we performed linear regression models between IAA, IS, and PCS plasma concentrations and
hemoglobin, the ESA dose over hemoglobin ratio (ESA/Hemoglobin) or the ESA resistance index (ERI). Third, we
used a polytomous logistic regression model to compare groups of patients with no/low/high ESA dose and
low/high hemoglobin statuses.
Results: Overall, 240 patients were included in the study. Mean age ± SD was 67.6 ± 16.0 years, 55.4% were men
and 42.5% had diabetes mellitus.
When compared with ESA treated patients, patients with no ESA had higher hemoglobin (mean 11.4 ± 1.1 versus
10.6 ± 1.2 g/dL; p <0.001), higher transferrin saturation (TSAT, 31.1 ± 16.3% versus 23.1 ± 11.5%; p < 0.001), less
frequently an IV iron prescription (52.1 versus 65.7%, p = 0.04) and were more frequently treated with
hemodiafiltration (53.5 versus 36.7%). In univariate analysis, IAA, IS or PCS plasma concentrations did not differ
between the two groups.
In the linear model, IAA plasma concentration was not associated with hemoglobin, but was negatively associated
with ESA/Hb (p = 0.02; R = 0.18) and with the ERI (p = 0.03; R = 0.17). IS was associated with none of the three
anemia parameters. PCS was positively associated with hemoglobin (p = 0.03; R = 0.14), but negatively with ESA/Hb
(p = 0.03; R = 0.17) and the ERI (p = 0.02; R = 0.19). In multivariate analysis, the association of IAA concentration
with ESA/Hb or ERI was not statistically significant, neither was the association of PCS with ESA/Hb or ERI.
Identically, in the subgroup of 76 patients with no inflammation (CRP <5 mg/L) and no iron deficiency (TSAT >20%)
linear regression between IAA, IS or PCS and any anemia parameter did not reach significance.
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In the third model, univariate analysis showed no intergroup significant differences for IAA and IS. Regarding PCS,
the Low Hb/High ESA group had lower concentrations. However, when we compared PCS with the other significant
characteristics of the five groups to the Low Hb/high ESA (our reference group), the polytomous logistic regression
model didn’t show any significant difference for PCS.
Conclusions: In our study, using three different statistical models, we were unable to show any correlation
between IAA, IS and PCS plasmatic concentrations and any anemia parameter in hemodialysis patients. Indolic
uremic toxins and PCS have no or a very low effect on anemia parameters.
Keywords: Anemia, Chronic hemodialysis, Uremic toxins, Erythropoietin, Indoxyl sulfate, Indolic solutes
Background
Anemia is a major burden in renal failure. Within pa-
tients with chronic kidney disease (CKD) stage 2 to 5,
anemia occurs in approximately 20% of patients but as
the kidney function decreases its prevalence rises to
more than 40% in patients with CKD stage 5 [1]. In the
Dialysis Outcomes and Practices Patterns Study
(DOPPS), around 90% of hemodialysis patients were
treated with erythropoiesis stimulating agents (ESA) in
2011 [https://www.dopps.org]. Clinical practice guide-
lines for anemia in CKD have recently been published by
the KDIGO [2].
The main reason for the defective erythropoiesis in
renal failure patients is the relative deficiency in erythro-
poietin (EPO) production by the peritubular cells of
kidneys [3]. Nevertheless, beside EPO deficiency, other
factors have been incriminated in anemia: deficiencies in
iron, folates and cobalamin, chronic inflammation, un-
controlled hyperparathyroidism, drugs including ACE
inhibitors, or uremic toxins [2–4]. It is important to
understand underlying mechanisms of anemia in CKD
because the use of ESA might be at least ineffective in
some patients or even deleterious in patients with high
dosages [5].
The uremic toxins, i.e. harmful compounds accumulat-
ing during renal failure, have been incriminated in the
pathophysiology of anemia in CKD: sera from uremic
patients inhibit hematopoietic progenitor’s growth. How-
ever, clinical data in the field are sparse [6].
The role of indolic toxins or paracresyl-sulfate (PCS)
in anemia has recently been proposed. Indoxyl sulfate
(IS) and indole-3-acetic acid (IAA) are protein bound in-
dolic uremic toxins derived from tryptophan. IS impairs
erythropoiesis in an HIF dependent manner and sup-
presses the EPO gene transcription during hypoxia [7].
This indolic toxin as well as IAA, activates the transcrip-
tion factor aryl hydrocarbon receptor (AhR) [8]. During
hypoxia, HIF2α forms a heterodimer with ARNT (AhR
nuclear transcriptor) and translocates in the nucleus
leading to EPO gene expression. IS increases the AhR/
ARNT complex in the nucleus and decreases the HIF2α/
ARNT complex [9]. Another mechanism leading to
anemia is induction of eryptosis by IS [10]. This mech-
anism has been proposed to favor anemia during renal
failure.
Beside these in vitro results, the role of indolic
toxins in anemia was also suggested by the use of
AST120. AST120 is an oral sorbent of several com-
pounds including indols. It decreases IS and PCS
blood concentrations. Wu et al. showed in a recent
clinical trial that AST120 decreased IS and PCS levels
and improved hemoglobin level [11]. Nevertheless, to
the best of our knowledge, no clinical study has
linked anemia or ESA resistance to plasma concentra-
tions of these specific uremic toxins.
In order to assess if IS, IAA and PCS are clinically im-
plicated in end-stage renal disease anemia we studied
the correlation between their plasmatic concentrations
with hemoglobin and ESA use in hemodialysis patients.
Methods
Subjects and study design
Between June and July 2014, we conducted an observa-
tional cross sectional study in two hemodialysis centers
in Marseille, France to analyze the correlation between
IS, IAA and PCS plasmatic concentrations and the
anemia parameters. The two centers were the Nephrol-
ogy Dialysis and Renal Transplant Center, Assistance
Publique des Hôpitaux de Marseille, and the Phocean
Institute of Nephrology.
All patients on hemodialysis for more than 3 months
and on either no ESA, or darbepoietin treatment were
included in the study. In order to compare ESA dose,
patient treated with other ESA’s than darbepoietin were
excluded from the study. Pregnant women and patients
aged <18 years were not included. According to French
law, it is not necessary or possible to obtain approval
from an ethics committee (Comité de Protection des
Personnes, CPP) for this type of non-interventional
study. Moreover, CPP ethics committees are not entitled
to issue waivers of approval for this type of study.
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Clinical, biological, and hemodialysis parameters
Clinical and biological following data were recorded
from the patient’s medical files: age, gender, nephropa-
thy, time on dialysis, history of diabetes mellitus, body
weight, biological parameters including hemoglobin,
transferrin saturation (TSAT), ferritin, as well as predia-
lysis solute concentrations as urea, creatinine, and β2-
microglobulin, dialysis parameters and vascular access
type, treatments including weekly ESA and IV iron
doses. Most classical factors associated with ESA resist-
ance as iron status, inflammation (c-reactive protein,
CRP), or parathormone level (PTH) were included in the
study [12].
Dialysis parameters (Kt/V and type of dialysis, i.e.
hemodialysis or hemodiafiltration) were recorded at the
mid-week session, and biological analyses were all per-
formed at the beginning of hemodialysis session. Dialysis
dose was estimated by a single-pool Kt/V (spKt/V), as
recommended by Daugirdas et al. [13].
Because anemia in hemodialysis patients is influenced
by ESA treatment and dose, two indexed dose-response
markers were calculated. First, the ESA dose over
hemoglobin ratio (ESA/Hb) was calculated as the weekly
dose of darbepoietin (μg) divided by the hemoglobin
plasma concentration (g/dL). Second, the ESA resistance
index (ERI), a well-known ESA quantification marker
associated with low survival in hemodialysis patients was
defined as ESA/Hb divided by post-dialysis weight (kg)
[12, 14–16]. In the two centers, IV iron (Ferric Hydrox-
ide Saccharose 100 mg/5 mL, Mylan®, USA) prescription
was based on TSAT and ferritin according to the physi-
cian’s decision.
Uremic toxins dosage
Serum and plasma samples from patients were stored at
−80 °C until use and determination of uremic solute. IS,
IAA, and paracresyl sulfate were measured in serum by
high performance liquid chromatography as previously
described [17]. β2-microglobulin was measured by
immuno-enzymology.
Statistical analysis
Quantitative data were expressed as mean ± standard
deviation (SD), whereas categorical data were expressed
as frequency and percentage.
In order to compare characteristics in the two groups
of patients: With ESA and Without ESA, univariate
group comparisons were performed using Student T-test
and chi-square tests.
To assess the correlation of toxins IS, IAA and PCS
plasmatic concentrations with hemoglobin and ESA use
in hemodialysis patients, two methods were used.
First, a multivariate Linear Regression model was used to
estimate the relationship between Hb, ESA/Hb or ERI
levels and the other characteristics. The β coefficients and
two tailed p-values were performed. The level of signifi-
cance was set at a p-value <0.05. This model was also
performed in the subgroup of patients with no inflamma-
tion (CRP <5 mg/L) and no iron deficiency (TSAT >20%).
Then, to better analyze this correlation, we performed a
Polytomous Logistic Regression model. We separated pa-
tients in 6 subgroups according to the hemoglobin level
and the ESA treatment. For each hemoglobin level (high
hemoglobin >10 g/dL and low hemoglobin ≤10 g/dL), we
separated the ESA treatment into 3 categories: no
treatment, low ESA dose <40 μg/week and high dose
≥40 μg/week. The 40 μg/week cutoff was chosen because
it was the median dose within patients receiving ESA. In
literature, hypo responsiveness to ESA is defined as a low
Hb despite high ESA dose, thus, the Low Hb/High ESA
group was taken as the reference group for the polyto-
mous logistic regression model. We introduced into the
multivariate model all the variables with a p-value <0.20 in
the univariate model, then we performed a backward
elimination procedure so as to conserve into the final
model only the variables with a p-value < 0.05. The ad-
justed odd ratios (OR) values with their 95% confidence
interval were performed, and the level of significance was
set at a p-value <0.05. Statistical analysis was performed
using Statistical Package for Social Sciences (SPSS) soft-
ware (version 20, SPSS, Inc., Chicago, IL, USA).
Results
Within the two hemodialysis centers, 240 patients were
included in the study. Mean age ± SD was
67.6 ± 16.0 years, 55.4% were men and 42.5% had
diabetes mellitus (Table 1). Mean time on dialysis was
82 ± 121 months.
The etiology of the primary cause of renal failure was
diabetic nephropathy in 23.8% of patients, vascular
nephropathy in 20.4%, chronic interstitial nephritis in
15.4%, non-diabetic glomerular disease in 12.9%, auto-
somal dominant polycystic kidney disease in 4.6%, other
in 6.7%, and unknown in 16.3%.
Clinical, dialysis and biological parameters are re-
ported in Table 1. Most of patients (63.3%) had a native
arteriovenous fistula, 20.0% a catheter and 16.7% an
arteriovenous graft. Mean Kt/V was of 1.51 ± 0.31,
which was in the recommended range of >1.2 [18].
Hemodiafiltration was the dialysis technique in 41.7% of
patients, and conventional hemodialysis for the
remaining 58.3%. Mean hemoglobin was 10.8 ± 1.2 g/dL,
mean TSAT 25.5 ± 13.5% and mean ferritin
530 ± 520 ng/mL. Mean albumin was 37.7 ± 5.3 g/L.
Mean IAA concentration was 4.73 ± 4.79 μmol/L; mean
IS concentration 93.3 ± 51.5 μmol/L and mean PCS
concentration 158 ± 99 μmol/L.
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Regarding treatments, 29.5% (n = 71 patients) had no
ESA and mean ESA dose in the treated group was
53.9 ± 50.0 μg per week (Table 1, Fig. 1); 61.7% of
patients had IV iron supplementation and mean iron
dose was of 232 ± 267 mg/month but most patients had
either no iron, or 400 mg/month (i.e. 100 mg/week)
(Table 1, Fig. 2).
When compared with ESA treated patients, patients
with no ESA had higher hemoglobin (mean 11.4 ± 1.1 ver-
sus 10.6 ± 1.2 g/dL; p-value <0.001), higher TSAT
(31.1 ± 16.3% versus 23.1 ± 11.5%; p < 0.001), less iron
prescription (52.1% versus 65.7%, p = 0.04) and they were
more frequently treated with hemodiafiltration (53.5% ver-
sus 36.7%) (Table 1). In univariate analysis, IAA, IS or
PCS plasma concentrations did not differ between the two
groups, thus, no multivariate model is provided.
Linear regression of IS, IAA and PCS with hemoglobin,
ESA over hemoglobin ratio and ERI are reported in Fig. 3.
IAA plasma concentration was not associated with crude
hemoglobin concentration, but was negatively associated
with ESA/Hb (p = 0.02; R = 0.18) and with the ERI
(p = 0.03; R = 0.17). IS was not associated with any of the
three anemia parameters. PCS was positively associated
with hemoglobin (p = 0.03; R = 0.14), and negatively with
Table 1 General characteristics and factors associated with ESA prescription: univariate analysis (Student T-test test or chi square test
as appropriate, n = 240 patients)
Total population (n = 240) Patients without ESA (n = 71) Patients with ESA (n = 169) p-value
Age (years) 67.6 ± 16.0 68.6 ± 14.8 67.3 ± 16.6 0.56
Male gender 55.4% 62.0% 52.7% 0.19
Time on dialysis (months) 82 ± 121 80 ± 89 83 ± 133 0.87
Diabetes mellitus 42.5% 43.7% 42.0% 0.81
Dry weight (kg) 69.6 ± 14.9 71.4 ± 15.6 68.9 ± 14.6 0.23
ADPKD 4.6% 4.2% 4.7% 1.00
White cell count (G/L) 7.01 ± 4.62 6.55 ± 2.05 7.21 ± 5.34 0.31
Lymphocytes (G/L) 1.28 ± 0.58 1.34 ± 0.62 1.25 ± 0.57 0.27
Hemoglobin (g/dL) 10.8 ± 1.2 11.4 ± 1.1 10.6 ± 1.2 <0.001
MCV (fl) 94 ± 8 93 ± 6 95 ± 8 0.33
Platelet count (G/L) 203 ± 79 187 ± 70 209 ± 82 0.06
TSAT (%) 25.5 ± 13.5 31.1 ± 16.3 23.1 ± 11.5 <0.001
Ferritin (ng/mL) 530 ± 520 577 ± 640 510 ± 461 0.36
Albumin (g/L) 37.7 ± 5.3 37.9 ± 4.8 37.6 ± 5.5 0.65
β2 microglobulin (mg/L) 26.6 ± 7.4 27.4 ± 7.9 26.4 ± 7.1 0.40
Parathormone (pg/mL) 256 ± 318 263 ± 313 252 ± 119 0.82
Predialysis creatinine (μmol/L) 732 ± 253 748 ± 273 725 ± 244 0.52
Predialysis urea (mmol/L) 20.7 ± 6.6 20.4 ± 5.9 20.8 ± 6.8 0.64
C-reactive protein (mg/L) 20.0 ± 43.5 16.6 ± 37.8 21.4 ± 45.7 0.44
IAA (μmol/L) 4.73 ± 4.79 4.79 ± 5.06 4.71 ± 4.69 0.91
IS (μmol/L) 93.3 ± 51.5 91.1 ± 53.0 94.2 ± 51.0 0.67
PCS(μmol/L) 158 ± 99 165 ± 99 154 ± 99 0.44
ESA dose (μg/w) - - 53.9 ± 50.0 -
IV iron medication (%) 61.7% 52.1% 65.7% 0.04
Iron dose (mg/mo) 232 ± 267 173 ± 200 257 ± 288 0.03
Vascular access
Native AV fistula 63.3% 54.9% 66.9% 0.17
AV graft 16.7% 18.3% 16.0%
Catheter 20.0% 26.8% 17.2%
HDF (%) 41.7% 53.5% 36.7% 0.02
Kt/V 1.51 ± 0.31 1.51 ± 0.26 1.51 ± 0.32 0.98
Results are provided as mean ± SD or percentages. ESA erythropoiesis stimulating agent, ADPKD autosomal dominant polycystic disease, MCV mean corpuscular
volume, IS indoxylsulfate, IAA indole-3-acetic acid, PCS paracresyl-sulfate, AV arteriovenous, HDF hemodiafiltration
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ESA/Hb (p = 0.03; R = 0.17) and the ERI (p = 0.02;
R = 0.19). In multivariate analysis, the association of IAA
concentration with ESA/Hb and ERI was not statistically
significant, neither was the association of PCS with ESA/
Hb and ERI. The only factors which were associated with
ESA/Hb and ERI in the multivariate analyses were age,
TSAT, ferritin, albumin and the iron dose (Table 2). Only
76 patients had no inflammation (CRP <5 mg/L) and no
iron deficiency (TSAT >20%). In this subgroup of patients,
univariate linear regression of IS, IAA and PCS with Hb,
ESA/Hb and ERI did not reach clinical significance (data
not shown).
To accurately analyze the link between anemia and
uremic toxins, patients were separated in 6 subgroups ac-
cording to the hemoglobin level and the ESA treatment as
described in the methods section. Frequencies and main
biological parameters are reported in Table 3. In the univar-
iate analysis, no intergroup significant difference was found
for IAA and IS. Regarding PCS, the Low Hb/High ESA
group had lower concentrations. However, when we
Fig. 1 ESA weekly dose in hemodialysis patients (n = 240 patients)
Fig. 2 IV iron monthly dose in hemodialysis patients (n = 240 patients)
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compared PCS with the other significant characteristics of
the five groups to the low Low Hb/High ESA (our reference
group), the polytomous logistic regression model didn’t
show any significant difference for PCS. In this latter, only
ferritin levels, TSAT and albumin differed between groups
as reported in Table 4.
Discussion
In this observational multicentric study including 240
hemodialysis patients, we report no correlation between
three protein bound uremic toxins -IAA, IS, and PCS-
and anemia or ESA responsiveness. Three types of
analyses were performed: first, we compared patients
treated with ESA and those not treated. In this analysis,
no correlation was found with the uremic toxins concen-
trations in the univariate model. Second, IAA, IS and
PCS concentrations were analyzed as continuous
variables. In the multivariate model, no link was found
between these concentrations and Hb, ESA/Hb or even
ERI. Finally, patients were divided in subgroups
Fig. 3 Association between Indole-3-acetic acid, Indoxyl Sulfate, and Paracresyl sulfate plasmatic concentrations and anemia parameters in
hemodialysis patients (Linear regression, n = 240 patients). IAA: Indole-3-acetic acid; IS: Indoxyl Sulfate; PCS: Paracresyl sulfate; ESA/Hb: Erythropoietin
Stimulating Agent weekly dose over hemoglobin ratio; ERI: Erythropoietin Stimulating Agent resistance index
Table 2 Factors associated with ESA/Hb and ERI: multivariate analyses (Linear Regression Model, n = 240 patients)
ESA/Hb (μg/g/dL) ERI (μg/kg/g/dL ×10)
Coefficient (95% CI) p-value Coefficient (95% CI) p-value
Age (per 10 years) −0.47 [−0.66; −0.28] 0.02 −0.09 [−0.12; −0.06] 0.006
TSAT −0.10 [−0.13; −0.07] <0.001 −0.02 [−0.02; −0.01] <0.001
Ferritin (per 10 ng/mL) 0.02 [0.03; 0.01] 0.003 0.004 [0.003; 0.005] 0.002
Albumin −0.27 [−0.33; −0.21] <0.001 −0.05 [−0.06; −0.04] <0.001
Iron dose 0.003 [0.002; 0.004] 0.004 0.001 [0.001; 0.001] 0.007
ESA/Hb ESA dose over hemoglobin ratio, ERI ESA resistance index, TSAT transferrin saturation
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according to their anemia/ESA status and there again,
no link was found between the studied uremic toxins
and anemia in this population.
Many in vitro data plead for an effect of uremic toxins
on erythropoiesis. Since years, it is well known that there
is a dose dependent inhibition cultured primary bone
marrow cell growth when serum extracted from renal
failure patients is added to the milieu [19, 20]. Neither
urea, nor creatinine were incriminated because they do
not show this effect [3]. Indolic solutes, especially IS
have been incriminated in anemia. Recently, Chiang et
al. have reported that IS reduces EPO production in
hypoxic condition by suppressing HIF activation and
subsequent EPO transcription [7]. These results were
confirmed in an independent study [21]. Recently the
effect of IS on HIF in response to ischemia was demon-
strated [22] as well as the key role of AhR in IS effect on
EPO transcription under hypoxic condition [9]. These
non-human experiments were important in vitro argu-
ments on the role of indolic uremic toxins on anemia.
To the best of our knowledge, only one clinical study has
focused on the correlation between IS level and anemia
until now. This study failed to identify a relation between
Table 3 Factors associated with high or low hemoglobin level and ESA dose (ANOVA or Chi-square test, n = 240 patients)
Hb >10 g/dL Hb ≤10 g/dL p-value
no ESA
(n = 63)
ESA ≤40 μg/w
(n = 75)
ESA >40 μg/w
(n = 41)
no ESA
(n = 8)
ESA ≤40 μg/w
(n = 25)
ESA >40 μg/w
(n = 28)
Age (years) 67.8 ± 15.3 67.1 ± 16.2 69.9 ± 15.4 74.5 ± 8.1 64.8 ± 17.6 65.9 ± 18.3 0.63
Gender (male) 61.9% 58.7% 41.5% 62.5% 64.0% 42.9% 0.19
Diabetes 44.4% 41.3% 43.9% 37.5% 48.0% 35.7% 0.96
Hemoglobin (g/dL) 11.6 ± 0.9 11.2 ± 0.8 11.1 ± 0.8 9.6 ± 0.6 9.5 ± 0.4 9.0 ± 0.9 <0.001
TSAT (%) 29.2 ± 13.5 23.5 ± 9.2 22.7 ± 11.1 45.8 ± 27.4 25.6 ± 9.8 20.1 ± 17.4 <0.001
Ferritin (ng/mL) 480 ± 330 426 ± 285 473 ± 304 1341 ± 1541 636 ± 314 677 ± 901 <0.001
Albumin (g/L) 38.4 ± 4.4 39.2 ± 4.1 37.5 ± 4.8 37.8 ± 4.6 33.0 ± 7.8 <0.001
β2 microglobulin (mg/L) 26.2 ± 7.0 25.7 ± 6.9 27.4 ± 8.2 34.1 ± 6.4 25.6 ± 6.2 27.4 ± 7.0 0.008
Parathormone (pg/mL) 268 ± 318 284 ± 315 195 ± 207 35.8 ± 9.8 264 ± 354 237 ± 438 0.83
Predialysis creatinine
(μmol/L)
764 ± 282 769 ± 242 684 ± 250 224 ± 299 757 ± 220 638 ± 239 0.08
Predialysis urea (mmol/L) 20.8 ± 5.9 21.7 ± 6.7 20.0 ± 6.5 623 ± 153 21.0 ± 6.1 19.6 ± 8.3 0.39
C-reactive protein (mg/L) 12.2 ± 18.9 12.7 ± 28.4 26.0 ± 67.4 17.2 ± 5.5 23.1 ± 49.9 36.5 ± 37.1 0.02
IAA (μmol/L) 5.10 ± 5.28 5.73 ± 5.97 3.51 ± 3.50 51.9 ± 97.3 4.67 ± 3.05 3.78 ± 2.60 0.09
IS (μmol/L) 92.8 ± 54.7 97.9 ± 45.2 100.9 ± 49.9 2.29 ± 1.30 85.2 ± 55.5 82.3 ± 61.9 0.54
PCS(μmol/L) 169 ± 101 172 ± 94 150 ± 97 78.1 ± 37.6 175 ± 98 96 ± 99 0.01
Iron medication
IV iron medication 54.0% 68.0% 73.2% 135 ± 75 48.0% 64.3% 0.10
Iron dose (mg/mo) 175 ± 188 228 ± 245 351 ± 318 163 ± 292 124 ± 167 314 ± 374 0.002
HDF (%) 54.0% 30.7% 31.7% 50.0% 52.0% 46.4% 0.05
Kt/V 1.51 ± 0.26 1.50 ± 0.28 1.50 ± 0.42 1.46 ± 0.30 1.57 ± 0.26 1.51 ± 0.34 0.95
Results are provided as mean ± SD or percentages. Hb Hemoglobin, ESA Erythropoietin stimulating agent, TSAT transferrin saturation, IAA indole-3-acetic acid,
IS indoxylsulfate, PCS paracresyl-sulfate, HDF hemodiafiltration
Table 4 Polytomous logistic regression: factors associated with
hemoglobin level or ESA requirement (n = 240 patients)
Predictor variables OR (95% CI) p-value
Hb > 10 g/dL no ESA TSAT (%) 1.1 [1.06–1.2] <0.001
Ferritin (ng/mL) 0.9 [0.8–0.9] <0.001
Albumin (g/L) 1.1 [1.04–1.2] 0.01
Hb ≤ 10 g/dL no ESA TSAT (%) 1.1 [1.05–1.2] <0.001
Ferritin (ng/mL) 0.9 [0.9–1.0] 0.06
Albumin (g/L) 1.0 [0.9–1.2] 0.5
Hb > 10 g/dL ESA low dose TSAT (%) 1.0 [1.01–1.1] 0.01
Ferritin (ng/mL) 0.9 [0.8–0.9] 0.006
Albumin (g/L) 1.2 [1.1–1.3] <0.001
Hb ≤ 10 g/dL ESA low dose TSAT (%) 1.0 [1.01–1.1] 0.05
Ferritin (ng/mL) 0.9 [0.9–1.0] 0.2
Albumin (g/L) 1.1 [1.02–1.2] 0.01
Hb ≤ 10 g/dL ESA high dose TSAT (%) 1.06 [0.9–1.1] 0.07
Ferritin (ng/mL) 0.9 [0.9–1.0] 0.05
Albumin (g/L) 1.1 [1.01–1.2] 0.02
The reference group is: Hb ≤ 10 g/dL ESA high dose
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IS concentration and anemia in patients on peritoneal dia-
lysis except in the non anuric patient’s subgroup in which
IS concentration was correlated with Hb level [23].
IS and PCS derive from the metabolism of tryptophan
and tyrosin respectively by bacteria within the gastro-
intestinal tract [24]. Hemodialysis patients without colon
have very low IS and PCS plasma concentrations, dem-
onstrating an important role of the gut in some uremic
toxins metabolism [25]. Plasma concentrations of these
toxins in renal failure patients are influenced by dietary
intakes [26] or the use of sorbents as AST-120 [27]. In
our study, IAA and PCS were associated with the ESA/
Hb ratio or the ERI in univariate analysis, but these
associations were no longer significant when adjusted on
other parameters including albumin, an important nutri-
tional maker. Parameters independently associated with
anemia parameters in hemodialysis patients were TSAT,
ferritin, and albumin. These parameters are the classical
parameters influencing ESA sensibility [12]. Other
parameters as CRP, β2-microglobulin or PTH did not
reach significance in our study.
AST120 -an oral sorbent of uremic toxins- improved
hemoglobin level in non-dialyzed CKD stage 5 patients
when compared to placebo although ESA doses
remained identical in the two groups [11]. This improve-
ment was attributed to IS and PCS which plasmatic
levels were lower in the AST-120 group. Nevertheless,
AST120 is a non-specific adsorbent and its effect cannot
definitely be attributed to these toxins removal because
it could be due to other adsorbed compounds.
It is not clear why IS, IAA and PCS exert an important
effect in vitro and no or a very low effect in vivo, but an
important clue is that in vitro experiments are often
performed with higher uremic toxin concentrations and
there might be a dose effect relationship between toxin
concentrations and anemia [7, 21].
Our study exerts some limits. First, we did not measure
free concentration of IS and PCS; however, effects of IS in
vitro is not influenced by albumin concentration in the
media [8], and in clinical studies the observed concentra-
tions of total and free IS are well correlated. Second, we
studied prevalent hemodialysis patients in which Hb was
performed every week and anemia very cautiously treated.
Results in incident hemodialysis or in non-dialysis patients
cannot be extrapolated from these results.
Conclusion
In conclusion, we were unable to show any correlation be-
tween IAA, IS and PCS plasmatic concentrations and
any anemia parameter in hemodialysis patients. It is
likely that indolic uremic toxins and PCS have no or
a very low effect on anemia parameters, i.e. Hb con-
centrations or ESA hypo responsiveness in this
population.
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